Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review

The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations. Aumolertinib has been shown to be a safe agent in the registry study. However, successful rechallenge with aumolertinib follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guijuan, Tang, Xiaoyuan, Zhang, Xingping, Qiu, Xingting, Lai, Qingwen, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414155/
https://www.ncbi.nlm.nih.gov/pubmed/36800249
http://dx.doi.org/10.1097/CAD.0000000000001496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414155/
https://www.ncbi.nlm.nih.gov/pubmed/36800249
http://dx.doi.org/10.1097/CAD.0000000000001496

Ejemplares similares